Con ten ts
01 Importance of collaboration in advancing personalized medicine
02 Current clinical challenges and (pre)clinical research on burns
03 Valorization
04 Ethical consideration and regulations
05 Academia industry partnerships
06 Overview of funding sources for collaborative research projects
07 Shared-decision making (SDM)
08 Principles of project management in collaborative research settings
09 Academic-Industry Partnerships
Partners in Innovation · study summary
, lecture 01
Im por tance of collabor ation in advancing
per sonalized m edicine
Partners in Innovation
Why is interdisciplinary collaboration important?
Improving patient outcomes
Acurate diagnosis -> genetic cause, precise treatments
Targeted therapies -> personalized care, less side effects
Enhanced monitoring -> genomics + clinical + digital, continuous adjustments
Accelerating research
Innovative drug development -> faster discovery, smarter therapeutic design
Translation to clinical practice -> better/faster outcomes, lab breakthroughs leading to patient care
Holistic understanding of disease -> prevention, precise diagnosis, personalized treatment
Value of diverse collaboration styles
Balancing strengths
Different styles complement each other
Phases of a project and collaboration styles
Initiation phase; plant (creative thinker) and shaper (driver)
Planning phase; coordinator (chairperson) and Monitor Evaluator (Analyzer)
Execution phase; implementer (organizer) and teamworker (supporter)
Review phase; completer finisher (detail-orienterd) and resource investigator (networker)
Increasing availability, accessibility, and affordability of innovative therapies through
collaboration
ATMPs (advanced therapy medicinal products)
More and more of these type of drugs are coming onto the market, but some of them are also withdrawn
from the market due to the high costs and regulatory challenges. For a lot of companies, it is too expensive
to keep the drug on the market. Availability remains an issue.
Companies charge very high prices (often millions) to recoup R&D investments; governments negotiate
pricing (using public tax money).
Development focuses on more common diseases → rare diseases are underrepresented and often
unprofitable.
Collaboration is key to solving these issues.
Development phases in therapy development
Discovery phase -> pre-clinical research -> clinical phase 1,2,3 -> commercial approval -> post-
marketing surveillance.
Pharma companies typically handle the last two steps, designed for large-scale drugs. For rare diseases,
academia often drives research since industry shows less interest.
2 critical phases for approval
Between pre-clinical research and a phase 1 clinical trial (in NL via CCMO)
Between phase 3 clinical trials and commercial approval
Identify relevant stakeholders
Who? Ethics boards/regulators (CCMO, CBG/EMA), researchers, patients, physicians, pharma companies, insurers,
etc.
Why? Stakeholders bring knowledge, networks, resources, and influence success.
Partners in Innovation · study summary
, Stakeholders mapping
Make a list of possible stakeholders
Analyze their interest and capacities.
Develop a connection and establish trust
Stakeholders are needed across the impact circle: societal, public, private, and policy.
Building networks requires active engagement—can’t rely only on internet searches.
Partnerships
To be impactful and sustainable, partnerships must be socially responsible:
Transparent pricing and data sharing.
Balancing profit margins with accessibility and affordability.
Ensuring fast but controlled patient access.
Example: The Emma Center for Personalized Medicine applies a socially responsible PPP model to accelerate rare
disease therapy development.
Cross-disciplinary collaborations
Cross-disciplinary collaborations are collaborations between different scientific disciplines. These collaborations
bring together the knowledge of laboratories, clinics, and companies to increase the effectiveness of research,
accelerate innovations, and improve patient care.
Roles
Laboratories: develop new technologies and conduct fundamental/translational research.
Clinics: carry out clinical studies and implement therapies.
Companies: scale up and commercialize innovations.
e.g. BioNTech and Pfizer’s covid-19 vaccine, the human genome project, etc.
Challenges
Rare diseases, language barrier, cultural differences, ethical and regulatory issues.
Best practices
Clear communication, shared goals, flexibility.
Effective cross-disciplinary collaboration requires good alignment between different experts and leads to
innovation and improved patient care
Partners in Innovation · study summary
01 Importance of collaboration in advancing personalized medicine
02 Current clinical challenges and (pre)clinical research on burns
03 Valorization
04 Ethical consideration and regulations
05 Academia industry partnerships
06 Overview of funding sources for collaborative research projects
07 Shared-decision making (SDM)
08 Principles of project management in collaborative research settings
09 Academic-Industry Partnerships
Partners in Innovation · study summary
, lecture 01
Im por tance of collabor ation in advancing
per sonalized m edicine
Partners in Innovation
Why is interdisciplinary collaboration important?
Improving patient outcomes
Acurate diagnosis -> genetic cause, precise treatments
Targeted therapies -> personalized care, less side effects
Enhanced monitoring -> genomics + clinical + digital, continuous adjustments
Accelerating research
Innovative drug development -> faster discovery, smarter therapeutic design
Translation to clinical practice -> better/faster outcomes, lab breakthroughs leading to patient care
Holistic understanding of disease -> prevention, precise diagnosis, personalized treatment
Value of diverse collaboration styles
Balancing strengths
Different styles complement each other
Phases of a project and collaboration styles
Initiation phase; plant (creative thinker) and shaper (driver)
Planning phase; coordinator (chairperson) and Monitor Evaluator (Analyzer)
Execution phase; implementer (organizer) and teamworker (supporter)
Review phase; completer finisher (detail-orienterd) and resource investigator (networker)
Increasing availability, accessibility, and affordability of innovative therapies through
collaboration
ATMPs (advanced therapy medicinal products)
More and more of these type of drugs are coming onto the market, but some of them are also withdrawn
from the market due to the high costs and regulatory challenges. For a lot of companies, it is too expensive
to keep the drug on the market. Availability remains an issue.
Companies charge very high prices (often millions) to recoup R&D investments; governments negotiate
pricing (using public tax money).
Development focuses on more common diseases → rare diseases are underrepresented and often
unprofitable.
Collaboration is key to solving these issues.
Development phases in therapy development
Discovery phase -> pre-clinical research -> clinical phase 1,2,3 -> commercial approval -> post-
marketing surveillance.
Pharma companies typically handle the last two steps, designed for large-scale drugs. For rare diseases,
academia often drives research since industry shows less interest.
2 critical phases for approval
Between pre-clinical research and a phase 1 clinical trial (in NL via CCMO)
Between phase 3 clinical trials and commercial approval
Identify relevant stakeholders
Who? Ethics boards/regulators (CCMO, CBG/EMA), researchers, patients, physicians, pharma companies, insurers,
etc.
Why? Stakeholders bring knowledge, networks, resources, and influence success.
Partners in Innovation · study summary
, Stakeholders mapping
Make a list of possible stakeholders
Analyze their interest and capacities.
Develop a connection and establish trust
Stakeholders are needed across the impact circle: societal, public, private, and policy.
Building networks requires active engagement—can’t rely only on internet searches.
Partnerships
To be impactful and sustainable, partnerships must be socially responsible:
Transparent pricing and data sharing.
Balancing profit margins with accessibility and affordability.
Ensuring fast but controlled patient access.
Example: The Emma Center for Personalized Medicine applies a socially responsible PPP model to accelerate rare
disease therapy development.
Cross-disciplinary collaborations
Cross-disciplinary collaborations are collaborations between different scientific disciplines. These collaborations
bring together the knowledge of laboratories, clinics, and companies to increase the effectiveness of research,
accelerate innovations, and improve patient care.
Roles
Laboratories: develop new technologies and conduct fundamental/translational research.
Clinics: carry out clinical studies and implement therapies.
Companies: scale up and commercialize innovations.
e.g. BioNTech and Pfizer’s covid-19 vaccine, the human genome project, etc.
Challenges
Rare diseases, language barrier, cultural differences, ethical and regulatory issues.
Best practices
Clear communication, shared goals, flexibility.
Effective cross-disciplinary collaboration requires good alignment between different experts and leads to
innovation and improved patient care
Partners in Innovation · study summary
